首页 > 最新文献

Drug and Therapeutics Bulletin最新文献

英文 中文
Statistical versus clinical significance: what is the (clinically important) difference? 统计学意义与临床意义：（临床重要）差异是什么？
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2026-02-05 DOI: 10.1136/dtb.2025.000055
Jacoby Patterson
{"title":"Statistical versus clinical significance: what is the (clinically important) difference?","authors":"Jacoby Patterson","doi":"10.1136/dtb.2025.000055","DOIUrl":"https://doi.org/10.1136/dtb.2025.000055","url":null,"abstract":"","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146124170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
VTE risk of newer contraceptives. 新避孕药具的静脉血栓栓塞风险。
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2026-01-28 DOI: 10.1136/dtb.2025.000058

Overview of: Yonis HGH, Mørch LS, Løkkegaard E, et al Contemporary Hormonal Contraception and Risk of Venous Thromboembolism. JAMA 2025;333:1358-61.

Yonis HGH, Mørch LS, Løkkegaard E，等。当代激素避孕与静脉血栓栓塞风险的研究综述。《美国医学会杂志》2025;333:1358 - 61。
{"title":"VTE risk of newer contraceptives.","authors":"","doi":"10.1136/dtb.2025.000058","DOIUrl":"10.1136/dtb.2025.000058","url":null,"abstract":"<p><p><b>Overview of:</b> Yonis HGH, Mørch LS, Løkkegaard E, <i>et al</i> Contemporary Hormonal Contraception and Risk of Venous Thromboembolism. <i>JAMA</i> 2025;333:1358-61.</p>","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"27"},"PeriodicalIF":0.0,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145965773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retracted studies in systematic reviews and meta-analyses. 在系统综述和荟萃分析中撤回的研究。
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2026-01-28 DOI: 10.1136/dtb.2025.000054

Overview of: Possamai CG, Cabanac G, Perrodeau E, et al Inclusion of Retracted Studies in Systematic Reviews and Meta-Analyses of Interventions: A Systematic Review and Meta-Analysis. JAMA Intern Med 2025;185:702-9.

综述：Possamai CG， Cabanac G， Perrodeau E等人在干预措施的系统综述和荟萃分析中纳入撤回研究：一项系统综述和荟萃分析。JAMA Intern Med 2025;185:702-9。
{"title":"Retracted studies in systematic reviews and meta-analyses.","authors":"","doi":"10.1136/dtb.2025.000054","DOIUrl":"10.1136/dtb.2025.000054","url":null,"abstract":"<p><p><b>Overview of:</b> Possamai CG, Cabanac G, Perrodeau E, <i>et al</i> Inclusion of Retracted Studies in Systematic Reviews and Meta-Analyses of Interventions: A Systematic Review and Meta-Analysis. <i>JAMA Intern Med</i> 2025;185:702-9.</p>","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"24"},"PeriodicalIF":0.0,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145667501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
▼ EURneffy epinephrine nasal spray. ▼EURneffy肾上腺素鼻喷雾剂。
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2026-01-27 DOI: 10.1136/dtb.2025.000044
{"title":"<b>▼</b> EURneffy epinephrine nasal spray.","authors":"","doi":"10.1136/dtb.2025.000044","DOIUrl":"https://doi.org/10.1136/dtb.2025.000044","url":null,"abstract":"","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146060814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Navigating the benefits and harms of GLP-1 and GLP-1/GIP agonists in obesity. GLP-1和GLP-1/GIP激动剂治疗肥胖症的利弊
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2026-01-09 DOI: 10.1136/dtb.2025.000039
Raymond O'Connor

Obesity is becoming increasingly common worldwide. Glucagon-like peptide-1 receptor agonist (GLP-1 RA) type drugs have the potential to help patients achieve considerable weight loss. Several benefits have been described in the short term, especially relating to diseases associated with obesity, where rapid weight loss results in undoubted improvements. These conditions include type 2 diabetes mellitus, cardiovascular disease and metabolic dysfunction-associated steatotic liver disease. Known adverse effects include gastrointestinal (nausea, vomiting, acute pancreatitis, dehydration and malnutrition), reduced efficacy of oral contraceptives and allergic reactions. Rarer adverse effects include thyroid cell tumours and non-arteritic anterior ischaemic optic neuropathy. Up to 33% of the weight lost is lean tissue mass (muscle and bone). Discontinuation rates can be up to 80% after 2 years. Subsequent weight regain can be up to two-thirds of prior weight loss. There is a risk of much of this regain being fatty tissue. To avoid this and associated malnutrition, GLP-1 RAs should only be initiated along with a supervised exercise programme and individualised dietetic advice. Subsequent patient monitoring to detect cessation, malnutrition and inappropriate fatty tissue weight gain is recommended.

肥胖在世界范围内变得越来越普遍。胰高血糖素样肽-1受体激动剂（GLP-1 RA）类药物有可能帮助患者实现相当大的体重减轻。在短期内已经描述了一些好处，特别是与肥胖相关的疾病，在这些疾病中，快速减肥无疑会带来改善。这些疾病包括2型糖尿病、心血管疾病和代谢功能障碍相关的脂肪变性肝病。已知的不良反应包括胃肠道（恶心、呕吐、急性胰腺炎、脱水和营养不良）、口服避孕药疗效降低和过敏反应。少见的不良反应包括甲状腺细胞肿瘤和非动脉性前缺血性视神经病变。高达33%的减重是瘦组织（肌肉和骨骼）。2年后停药率可达80%。随后的体重反弹可能达到之前体重下降的三分之二。这种重新获得的脂肪组织有很大的风险。为了避免这种情况和相关的营养不良，GLP-1 RAs只能在有监督的锻炼计划和个性化饮食建议的情况下开始。建议对患者进行后续监测，以发现戒烟、营养不良和不适当的脂肪组织体重增加。
{"title":"Navigating the benefits and harms of GLP-1 and GLP-1/GIP agonists in obesity.","authors":"Raymond O'Connor","doi":"10.1136/dtb.2025.000039","DOIUrl":"https://doi.org/10.1136/dtb.2025.000039","url":null,"abstract":"<p><p>Obesity is becoming increasingly common worldwide. Glucagon-like peptide-1 receptor agonist (GLP-1 RA) type drugs have the potential to help patients achieve considerable weight loss. Several benefits have been described in the short term, especially relating to diseases associated with obesity, where rapid weight loss results in undoubted improvements. These conditions include type 2 diabetes mellitus, cardiovascular disease and metabolic dysfunction-associated steatotic liver disease. Known adverse effects include gastrointestinal (nausea, vomiting, acute pancreatitis, dehydration and malnutrition), reduced efficacy of oral contraceptives and allergic reactions. Rarer adverse effects include thyroid cell tumours and non-arteritic anterior ischaemic optic neuropathy. Up to 33% of the weight lost is lean tissue mass (muscle and bone). Discontinuation rates can be up to 80% after 2 years. Subsequent weight regain can be up to two-thirds of prior weight loss. There is a risk of much of this regain being fatty tissue. To avoid this and associated malnutrition, GLP-1 RAs should only be initiated along with a supervised exercise programme and individualised dietetic advice. Subsequent patient monitoring to detect cessation, malnutrition and inappropriate fatty tissue weight gain is recommended.</p>","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145942999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hyperbolic tapering of antidepressants: where are we now? 抗抑郁药的双曲递减：我们现在在哪里？
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2025-12-22 DOI: 10.1136/dtb.2024.000065
Mark Horowitz, Michael Wilcock
{"title":"Hyperbolic tapering of antidepressants: where are we now?","authors":"Mark Horowitz, Michael Wilcock","doi":"10.1136/dtb.2024.000065","DOIUrl":"10.1136/dtb.2024.000065","url":null,"abstract":"","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"3-7"},"PeriodicalIF":0.0,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145480844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Choroidal effusion after initiation of topical dorzolamide treatment. 局部多唑胺治疗开始后脉络膜积液。
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2025-12-22 DOI: 10.1136/dtb.2025.262168rep
Derrick James Wang, Peter Feng Chen, Weilin Chan, Gloria P Fleming
{"title":"Choroidal effusion after initiation of topical dorzolamide treatment.","authors":"Derrick James Wang, Peter Feng Chen, Weilin Chan, Gloria P Fleming","doi":"10.1136/dtb.2025.262168rep","DOIUrl":"10.1136/dtb.2025.262168rep","url":null,"abstract":"","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"13-15"},"PeriodicalIF":0.0,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144752672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Disinformation and misinformation: what can we do? 虚假信息和错误信息：我们能做些什么？
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2025-12-22 DOI: 10.1136/dtb.2025.000047
Syba Sunny
{"title":"Disinformation and misinformation: what can we do?","authors":"Syba Sunny","doi":"10.1136/dtb.2025.000047","DOIUrl":"https://doi.org/10.1136/dtb.2025.000047","url":null,"abstract":"","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":"64 1","pages":"2"},"PeriodicalIF":0.0,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145809643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral contraception and GLP-1 agonists. 口服避孕药和GLP-1激动剂。
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2025-12-22 DOI: 10.1136/dtb.2025.000049

Overview of: Faculty of Sexual and Reproductive Healthcare. FSRH statement: Glucagon-like peptide-1 (GLP-1) agonists and oral contraception [online], 2025. Available: https://www.cosrh.org/Public/Documents/FSRH-statement-Glucagon-like-peptide-1-agonists-and-oral-contraception-Feb-2025.aspx [Accessed 26 September 2025].

概述：性与生殖保健学院。FSRH声明：胰高血糖素样肽-1 （GLP-1）激动剂和口服避孕药[在线]，2025。可获取：https://www.cosrh.org/Public/Documents/FSRH-statement-Glucagon-like-peptide-1-agonists-and-oral-contraception-Feb-2025.aspx[2025年9月26日访问]。
{"title":"Oral contraception and GLP-1 agonists.","authors":"","doi":"10.1136/dtb.2025.000049","DOIUrl":"10.1136/dtb.2025.000049","url":null,"abstract":"<p><p><b>Overview of:</b> Faculty of Sexual and Reproductive Healthcare. FSRH statement: Glucagon-like peptide-1 (GLP-1) agonists and oral contraception [online], 2025. Available: https://www.cosrh.org/Public/Documents/FSRH-statement-Glucagon-like-peptide-1-agonists-and-oral-contraception-Feb-2025.aspx [Accessed 26 September 2025].</p>","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145367663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Topiramate-induced acute eosinophilic pneumonia. 托吡酯诱导的急性嗜酸性肺炎。
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2025-12-22 DOI: 10.1136/dtb.2025.261220rep
Rahul Tyagi, Monika Aggarwal, Utkarsh Suyal, Indramani Pandey
{"title":"Topiramate-induced acute eosinophilic pneumonia.","authors":"Rahul Tyagi, Monika Aggarwal, Utkarsh Suyal, Indramani Pandey","doi":"10.1136/dtb.2025.261220rep","DOIUrl":"10.1136/dtb.2025.261220rep","url":null,"abstract":"","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"9-12"},"PeriodicalIF":0.0,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
Drug and Therapeutics Bulletin
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1